Zyven OD (Pristiq / Desvenlafaxine) 50 Mg – 100 tablet

USD $66.55

Each Zyven OD Tablet contains 50 mg Desvenlafaxine with 100 tablets a box used in the treatment of major depressive disorders.

ATC Classification: N06AX23
Active Ingrediant: Desvenlafaxine
Generic Name: Zyven OD
Manufacturer: Zydus
Strength: 50 Mg
Dosage Type: Tablet
Packaging Type: Blister in Box
Contains: 100 Tabs

Important update for customers in the USA:

The World has stopped all packages mailing to the USA due to De Minimus Exemption.

  1. This situation is real and affects the world, not just India. See your local news or this Fox Business report .
  2. We got through COVID; we will get through this as well.
  3. By law we must temporarily remove Card and eCheck for USA shipments because we cannot mail today.
  4. Suggestion: order now to hold your place — shipping will be first-come, first-served once mailing resumes (mail is already queued).
  5. Waiting to place your order is fine; we expect resolution soon, but mail is piling up worldwide, not only with our firm.
  6. We ship normally to the UK, AUS, Japan, and most others. The hold is on the USA side only.
Thanks for your patience.
Examples of Packages sent

 

Pronunciation

(des ven la FAX een)

 

Medication Safety Issues

Sound-alike/look-alike issues:

Pristiq may be confused with PriLOSEC

Geriatric Patients: High-Risk Medication:

Beers Criteria: Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs) are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to its potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2019]).

 

Storage/Stability

Store at 20?C to 25?C (68?F to 77?F); excursions permitted to 15?C to 30?C (59?F to 86?F).

 

Adverse Reactions

>10%:

Central nervous system: Dizziness (10% to 13%), insomnia (9% to 12%)

Dermatologic: Hyperhidrosis (10% to 11%)

Gastrointestinal: Nausea (22% to 26%), xerostomia (11% to 17%)

1% to 10%:

Cardiovascular: Orthostatic hypotension (elderly 8%), syncope (<2%), tachycardia (<2%), hypertension (dose related; ?1% of patients taking 50 to 100 mg daily had sustained diastolic BP ?90 mm Hg)

Central nervous system: Drowsiness (?9%), fatigue (7%), anxiety (3% to 5%), delayed ejaculation (1% to 5%), abnormal dreams (2% to 3%), anorgasmia (males ?3%; females 1%), jitteriness (2%), vertigo (?2%), depersonalization (<2%), dystonia (<2%), seizure (<2%), disturbance in attention (1%), yawning (1%), male sexual disorder (?1%)

Dermatologic: Alopecia (<2%), skin photosensitivity (<2%), skin rash (<2%)

Endocrine & metabolic: Decreased libido (males 4% to 5%), increased serum cholesterol (increased by ?50 mg/dL and ?261 mg/dL: 3% to 4%), increased serum prolactin (<2%), weight gain (<2%), hot flash (1%), increased LDL cholesterol (increased by ?50 mg/dL and ?190 mg/dL: ?1%)

Gastrointestinal: Constipation (9%), decreased appetite (5% to 8%), vomiting (?4%), bruxism (<2%)

Genitourinary: Proteinuria (5% to 8%), erectile dysfunction (3% to 6%), urinary retention (<2%), ejaculation failure (?1%), urinary hesitancy (?1%)

Hepatic: Abnormal hepatic function tests (<2%)

Hypersensitivity: Angioedema (<2%)

Neuromuscular & skeletal: Tremor (?3%), stiffness (<2%), weakness (<2%)

Ophthalmic: Blurred vision (3% to 4%), mydriasis (2%)

Otic: Tinnitus (?2%)

Frequency not defined: Cardiovascular: Coronary occlusion, ischemic heart disease, myocardial infarction

<1%, postmarketing, and/or case reports: Acute pancreatitis, angle-closure glaucoma, cardiomyopathy (takotsubo), Stevens-Johnson syndrome

Additional information

Active Ingrediant

Generic Name

Alternate Names

, , , , , , , , , , , , ,

Strength

Dosage Type

Packaging Type

Brand

Zydus

Reviews

There are no reviews yet

Be the first to review “Zyven OD (Pristiq / Desvenlafaxine) 50 Mg – 100 tablet”

Your email address will not be published. Required fields are marked *